Page 14 - Robert Lustig News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novo Nordisk, a Danish pharmaceutical company renowned for its diabetes medicines, is now positioning itself as the world's leading weight-loss company. The company aims to target the global population of 764 million people with obesity, with the United States being its most lucrative market. In the U.S., where over two-thirds of adults are either overweight or obese, Novo charges customers $1,300 per month for the weekly injection of Wegovy.

Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the American obesity crisis: their prescription pads. Counseling on...

The Pharmaceutical giant behind obesity drug Wegovy has shelled out millions of dollars to incentivize doctors to prescribe the medicine, an analysis has found.

GLP-1 drugs like Ozempic and Wegovy have garnered consumer attention for their ability to curb unhealthy food and beverage cravings, leading to weight loss, as large CPG companies and major retailers might be able to use the moment to refocus on providing better-for-you and healthier options.

Food and beverage industry stakeholders are debating the role and importance of ultra-processed foods (UPFs) as consumers signal a willingness to try healthier versions of these products.